Back to search results

Pancreatic Cancer Detection Consortium

This study is looking for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) to help test a new diagnostic method called PANcreatic cancer Exosome Early detectiON (PANXEON). This test analyzes specific genetic material (miRNAs) in your blood to see if it can detect pancreatic cancer early. The goal is to confirm if this test can accurately identify pancreatic cancer in its early stages. You can join if you are 18 or older, have a confirmed diagnosis of pancreatic ductal adenocarcinoma (stages I-IV), and have not yet started treatment. The study aims to enroll 2000 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information without giving you a specific treatment. It aims to enroll 2000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to measure the test's sensitivity through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06388967

Pancreatic Cancer Detection Consortium

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~2,000 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:PANcreatic cancer Exosome Early detectiON (PANXEON)

At a glance

Recruiting sites
11 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity
Measured over Through study completion, an average of 1 year

Conditions

Pancreatic Cancer
Pancreatic Carcinoma
Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasms
Pancreatic Cancer Stage I
Pancreatic Cancer Stage
Pancreatic Cancer Resectable
Pancreatic Cancer Stage 0
Pancreatic Cancer Stage II
Pancreatic Cancer Stage III
Pancreatic Cancer, Adult
Pancreatic Cancer Non-resectable

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT06388967

Where you'd take part

This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Asan Medical Center

    Seoul, South Koreastudy coordinator listed

    Recruiting

  • Atlantic Health System

    Morristown, New Jerseystudy coordinator listed

    Recruiting

  • City of Hope Medical Center

    Monrovia, Californiastudy coordinator listed

    Recruiting

  • Hoag Center

    Newport Beach, Californiastudy coordinator listed

    Recruiting

  • Honorhealth

    Scottsdale, Arizonastudy coordinator listed

    Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsinstudy coordinator listed

    Recruiting

  • Nagoya University

    Nagoya, Japanstudy coordinator listed

    Recruiting

  • Ochsner Medical Center

    Jefferson, Louisianastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ajay Goel, PhD
[email protected]
6262183452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Exclusion

Lack of written informed consent.

What this trial measures

  • SensitivityThrough study completion, an average of 1 year

    True positive rate: the probability of a positive test result, conditioned on the individual truly being positive